Opinion
Video
Mohit Khera, MD, MBA, MPH, on the impact of the TRAVERSE trial
Author(s):
Key Takeaways
- The TRAVERSE trial is the largest randomized placebo-controlled study on testosterone therapy, impacting clinical perspectives on its risks and benefits.
- The study alleviates concerns about cardiovascular risks, such as myocardial infarction, and shows no increased risk of prostate cancer or urinary symptoms.
"The TRAVERSE trial is the largest randomized placebo-controlled trial ever published in men receiving testosterone vs placebo," says Mohit Khera, MD, MBA, MPH.
In this video, from the 2024 Sexual Medicine Society of North America (SMSNA) Fall Scientific Meeting in Scottsdale, Arizona, Mohit Khera, MD, MBA, MPH, discusses the impact of the TRAVERSE trial on his clinical practice. Khera is a professor of urology at Baylor College of Medicine in Houston, Texas, and the current president of the SMSNA.
Transcription:
How have the findings from the TRAVERSE study affected your clinical practice?
The TRAVERSE trial is the largest randomized placebo-controlled trial ever published in men receiving testosterone vs placebo. This study has made a dramatic impact on the way I think about testosterone and its overall risks and benefits. In terms of cardiovascular risk, there's no more concern for cardiovascular risk, meaning an MI. We also note that this TRAVERSE trial showed that there was no increased risk in prostate cancer or worsening of urinary symptoms. There were some benefits that we saw through the TRAVERSE trial. One was sexual function, and the other was slight improvements in depression as well.
This transcript was AI generated and edited by human editors for clarity.
